Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Concomitant use of voriconazole and rifabutin in a patient with multiple infections.

Schwiesow JN, Iseman MD, Peloquin CA.

Pharmacotherapy. 2008 Aug;28(8):1076-80. doi: 10.1592/phco.28.8.1076.

PMID:
18657024
2.

Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy.

Thors VS, Bierings MB, Melchers WJ, Verweij PE, Wolfs TF.

Pediatr Infect Dis J. 2011 Mar;30(3):268-70. doi: 10.1097/INF.0b013e3182037879.

PMID:
21127455
3.

Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.

Howard A, Hoffman J, Sheth A.

Ann Pharmacother. 2008 Dec;42(12):1859-64. doi: 10.1345/aph.1L243. Epub 2008 Nov 18. Review.

PMID:
19017830
4.

Breakthrough lung Scedosporium prolificans infection with multiple cavity lesions in a patient receiving voriconazole for probable invasive aspergillosis associated with monoclonal gammopathy of undetermined significance (MGUS).

Ohashi R, Kato M, Katsura Y, Takekawa H, Hoshika Y, Sugawara T, Yoshimi K, Togo S, Nagaoka T, Seyama K, Takahashi K, Tsuchiya K, Misawa S, Kikuchi K.

Med Mycol J. 2011;52(1):33-8.

5.

Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.

Berge M, Guillemain R, Boussaud V, Pham MH, Chevalier P, Batisse A, Amrein C, Dannaoui E, Loriot MA, Lillo-Le Louet A, Billaud EM.

Transpl Infect Dis. 2009 Jun;11(3):211-9. doi: 10.1111/j.1399-3062.2009.00384.x. Epub 2009 Mar 17.

PMID:
19302272
6.

Management of voriconazole hepatotoxicity in a lung transplant patient.

Belaiche S, Roustit M, Bedouch P, Quetant S, Saint-Raymond C, Pison C.

Transpl Infect Dis. 2011 Jun;13(3):309-11. doi: 10.1111/j.1399-3062.2010.00590.x. Epub 2010 Dec 22.

PMID:
21176020
7.
8.

In vitro-in vivo correlation of voriconazole resistance due to G448S mutation (cyp51A gene) in Aspergillus fumigatus.

Krishnan Natesan S, Wu W, Cutright JL, Chandrasekar PH.

Diagn Microbiol Infect Dis. 2012 Nov;74(3):272-7. doi: 10.1016/j.diagmicrobio.2012.06.030. Epub 2012 Aug 14.

PMID:
22897872
9.
10.

Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.

Harnicar S, Adel N, Jurcic J.

J Oncol Pharm Pract. 2009 Sep;15(3):175-82. doi: 10.1177/1078155208101959. Epub 2009 Mar 12.

PMID:
19282418
11.

Case report 2: Fungal infections in chronic obstructive pulmonary disease.

Meersseman W.

Mycoses. 2010 Jul;53 Suppl 2:6-7. doi: 10.1111/j.1439-0507.2010.01907.x. No abstract available.

PMID:
20591012
12.

Hyperpigmentation in a patient with AIDS, receiving rifabutin for disseminated Mycobacterium genavense infection.

Figueras C, Garcia L, Bertran JM.

Eur J Pediatr. 1998 Jul;157(7):612. No abstract available.

PMID:
9686833
13.
14.

[Cerebral aspergillosis in an HIV-infected patient: unsuccessful outcome despite combined antifungal therapy. ].

Gasch O, Fernández N, Ayats J, Santin M.

Enferm Infecc Microbiol Clin. 2009 Mar;27(3):193-4. doi: 10.1016/j.eimc.2008.01.002. Epub 2009 Feb 13. Spanish. No abstract available.

PMID:
19306722
15.

Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.

Cadranel J, Philippe B, Hennequin C, Bergeron A, Bergot E, Bourdin A, Cottin V, Jeanfaivre T, Godet C, Pineau M, Germaud P.

Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3231-9. doi: 10.1007/s10096-012-1690-y. Epub 2012 Jul 11.

16.

Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.

Takemoto K, Yamamoto Y, Ueda Y, Kanazawa K, Yoshida K, Niki Y.

Chemotherapy. 2009;55(2):105-13. doi: 10.1159/000194661. Epub 2009 Jan 19.

PMID:
19151551
17.

Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Moon SM, Park HY, Jeong BH, Jeon K, Lee SY, Koh WJ.

Antimicrob Agents Chemother. 2015 Jan;59(1):663-5. doi: 10.1128/AAC.04075-14. Epub 2014 Oct 13.

18.
19.

Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.

Boyd NK, Zoellner CL, Swancutt MA, Bhavan KP.

Antimicrob Agents Chemother. 2012 Nov;56(11):6001-2. doi: 10.1128/AAC.00700-12. Epub 2012 Aug 13.

20.

[Effects of voriconazole and vascular lesions in invasion of aspergillosis into the central nerve system].

Ueno A, Hamano T, Fujii A, Matsunaga A, Naganuma S, Yoneda M, Itoh H, Kuriyama M.

Rinsho Shinkeigaku. 2009 Aug;49(8):468-73. Japanese.

PMID:
19827595
Items per page

Supplemental Content

Write to the Help Desk